Alpha-synucleinopathy is an umbrella term for a group of neurodegenerative diseases defined by the abnormal buildup of a misfolded protein called alpha-synuclein in the brain. The three main conditions under this umbrella are Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Although these diseases look quite different in the clinic, they share a common molecular villain: clumps of alpha-synuclein that accumulate in nerve cells or support cells, progressively damaging the brain. What makes the field especially interesting right now is a growing body of evidence that the specific shape of those clumps may determine which disease you get.
What Alpha-Synuclein Normally Does
Alpha-synuclein is one of the most abundant proteins in nerve cells. It concentrates at the tips of neurons, right at the junctions where one nerve cell communicates with another. Its exact role is still under active investigation, but researchers believe it helps regulate the release of chemical messengers between neurons and assists with the recycling of the tiny packages those messengers travel in.1PubMed Central. The Synaptic Function of α-Synuclein In healthy brains, alpha-synuclein is flexible and soluble, doing its job and getting cleared away without issue. Problems begin when it starts to misfold.
How Misfolding Leads to Disease
Under certain conditions, alpha-synuclein molecules begin changing shape and sticking to each other. They first form small clusters called oligomers, which can grow into longer thread-like structures called fibrils. Research has established that among these different forms, the small oligomers and short fibrils are the most toxic to neurons. These species can damage cell membranes, disrupt energy production inside cells, and trigger inflammatory responses.2PubMed Central. All-or-none amyloid disassembly via chaperone-triggered fibril unzipping favors clearance of α-synuclein toxic species Making things worse, toxic oligomers can also be released from fibrils after they have already formed, meaning even mature clumps continue to shed harmful material.3Nature Communications. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells
Healthy cells have cleanup systems designed to break down and dispose of faulty proteins. Two main garbage-disposal pathways handle alpha-synuclein under normal circumstances. But the various shapes that misfolded alpha-synuclein takes create a bottleneck: the cleanup machinery struggles with the sheer diversity of aggregate forms, and the buildup outpaces the cell’s ability to clear it.4PubMed. Role of Ubiquitin-Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance Once that balance tips, aggregates accumulate, nerve cells start to sicken, and the disease process is underway.
The Prion-Like Spread
One of the most striking discoveries of the past two decades is that misfolded alpha-synuclein does not just sit where it forms. It can travel from one nerve cell to the next and force the normal protein in those receiving cells to misfold as well. This behavior is sometimes called “prion-like” because it resembles the way prion proteins spread in diseases like mad cow disease. In animal experiments, injecting synthetic alpha-synuclein fibrils into one brain region triggers a wave of pathology that fans out through connected brain areas over weeks and months.5Brain. Prion-like spreading of pathological α-synuclein in brain The injected human fibrils disappeared within about a week, yet the mouse’s own alpha-synuclein kept accumulating in abnormal, modified forms for months afterward, showing that the disease process had taken on a life of its own.
The pattern of this spread is not random. Studies using mouse models show that pathology follows the brain’s wiring: regions with dense nerve connections to the starting point get hit next, and areas that produce more alpha-synuclein on their own are more vulnerable.6PubMed Central. Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis This helps explain why different synucleinopathies affect different brain circuits and produce different symptoms depending on where the process starts and which connections it exploits.7PubMed Central. Alpha-synuclein spreading in Parkinson’s disease
Parkinson’s Disease
Parkinson’s disease is the most common synucleinopathy, affecting millions of people worldwide. Its hallmark is the progressive loss of dopamine-producing neurons in a small brain region called the substantia nigra. As those neurons die, dopamine levels drop, and movement becomes increasingly difficult: tremor, stiffness, slowness, and balance problems emerge. Under a microscope, the nerve cells that remain are riddled with round protein deposits called Lewy bodies and threadlike Lewy neurites, both made primarily of aggregated alpha-synuclein.
But Parkinson’s is far more than a movement disorder. Many patients develop depression, loss of smell, constipation, sleep disturbances, and eventually cognitive decline. In fact, some of these non-motor symptoms appear years or even decades before the characteristic tremor, suggesting that the disease process begins long before the substantia nigra is severely damaged.
Dementia with Lewy Bodies
Dementia with Lewy bodies shares the same protein pathology as Parkinson’s, with Lewy bodies and Lewy neurites spread through the brain.8PubMed Central. Dementia with Lewy bodies: an update and outlook The practical distinction between the two diagnoses rests on timing. In dementia with Lewy bodies, cognitive problems either come first or appear within the first year alongside any movement symptoms. In Parkinson’s disease dementia, cognitive decline shows up more than a year after motor symptoms are already established.9PubMed Central. Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies This one-year rule is admittedly arbitrary, and there has been longstanding debate about whether these are truly separate diseases or different expressions of the same underlying process.10PubMed. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Imaging and autopsy studies do reveal some biological differences. Dementia with Lewy bodies tends to show more cortical brain shrinkage, a heavier burden of Lewy pathology in the cortex and limbic regions, and a higher likelihood of also harboring Alzheimer’s-type pathology compared to Parkinson’s disease dementia.10PubMed. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies Those extra pathologies may explain why cognitive symptoms appear earlier and tend to be more severe in dementia with Lewy bodies.
Multiple System Atrophy
Multiple system atrophy stands apart from the other synucleinopathies in a key way: the alpha-synuclein deposits pile up not in neurons but in oligodendrocytes, the support cells responsible for insulating nerve fibers in the brain’s white matter.11PubMed. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein These deposits, called glial cytoplasmic inclusions, appear to precede the nerve cell death that follows.12PubMed Central. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions Why alpha-synuclein accumulates inside these support cells rather than neurons is still not well understood, and it remains one of the biggest open questions in the field.
Multiple system atrophy tends to progress faster than Parkinson’s disease and can manifest as either a movement-dominant form (resembling stiff, slow parkinsonism that responds poorly to medication) or a balance-and-coordination-dominant form (resembling cerebellar ataxia). Autonomic nervous system failure, causing problems like severe drops in blood pressure upon standing, urinary dysfunction, and impaired temperature regulation, is common in both forms.
Different Protein Shapes, Different Diseases
One of the most compelling recent developments in synucleinopathy research is the “strain” hypothesis. The basic idea: alpha-synuclein fibrils can fold into structurally distinct shapes, and these shapes behave differently when introduced into the brain. Researchers have amplified alpha-synuclein from the brains of patients who died with Parkinson’s, dementia with Lewy bodies, or multiple system atrophy, and found that the fibrils from each disease have measurably different structural properties.13Nature Communications. Seed amplification of MSA alpha-synuclein aggregates preserves the biological and structural properties of brain-derived aggregates
When these patient-derived strains were injected into animal brains, the results mirrored the clinical differences between the diseases. Strains from multiple system atrophy patients were the most aggressive, causing more severe movement problems, more widespread pathology, and more neurodegeneration. Parkinson’s strains produced moderate effects. Strains from dementia with Lewy bodies were the mildest in the animal models tested.14PubMed Central. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies There is also more structural variety among Parkinson’s-derived fibrils compared to those from multiple system atrophy, which could help explain why Parkinson’s disease is clinically more heterogeneous.15Nature Communications. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts
Why the Gut Matters
A hypothesis first proposed by neuroanatomist Heiko Braak suggests that in at least some people, synucleinopathy may start not in the brain but in the gut. Abnormal alpha-synuclein has been detected in enteric nerves, the nerve network lining the intestinal wall, before it shows up in the brain.16PubMed Central. Parkinson’s disease from the gut The vagus nerve, which connects the gut to the brainstem, appears to serve as a highway for misfolded alpha-synuclein to travel upward. In mouse models, injecting alpha-synuclein fibrils into the intestinal wall leads to pathology appearing along the vagus nerve and eventually reaching the brain.17PubMed Central. Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson’s disease
This fits with the observation that constipation and other gut symptoms often precede motor symptoms in Parkinson’s by many years. The Braak hypothesis does not explain every case — some patients develop brain pathology without detectable gut involvement — but it offers one plausible route for how the disease process initiates.18Nature Reviews Neurology. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Genetic Risk Factors
Most synucleinopathies are not directly inherited, but genetics play a measurable role in risk. The most straightforward genetic link involves the SNCA gene, which encodes alpha-synuclein itself. Certain point mutations in SNCA can cause the protein to misfold more readily, and duplication or triplication of the gene means cells produce too much normal protein, which also overwhelms the cleanup systems and leads to aggregation. Triplication of SNCA causes an aggressive form of Parkinson’s disease with dementia, and neurons derived from patients with this triplication produce double the amount of alpha-synuclein compared to neurons from unaffected relatives.19Nature Communications. Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus Even duplications, which produce less excess protein, can cause disease.20PubMed Central. Autosomal dominant Parkinson’s disease caused by SNCA duplications
Another important genetic player is the GBA gene, which codes for an enzyme involved in breaking down fats inside cellular recycling compartments. When GBA is mutated, the recycling machinery becomes sluggish, and alpha-synuclein that would normally be cleared instead accumulates.21PubMed Central. GBA Variants and Parkinson Disease: Mechanisms and Treatments Intriguingly, some GBA variants cause alpha-synuclein aggregation even without loss of the enzyme’s activity, suggesting the mutant protein itself may be doing additional harm.22PubMed Central. The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines GBA mutations are now recognized as the most common known genetic risk factor for Parkinson’s disease, and they are also overrepresented in dementia with Lewy bodies.
Environmental Factors
Pesticide exposure has been associated with Parkinson’s disease across multiple studies, although pinning down exactly which chemicals are responsible is difficult given the thousands of registered products in the United States alone.23PubMed Central. Identification of pesticides associated with an increased risk of Parkinson’s disease using a multi-screen approach One case-control study found that pesticide exposure was linked to Parkinson’s in younger subjects specifically, with herbicide exposure roughly doubling the odds. Both genetic susceptibility at the SNCA gene and pesticide exposure contributed independently to risk in that study.24PubMed. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study The current thinking is that genes and environmental exposures interact: some people may be genetically primed for alpha-synuclein misfolding, and an environmental insult tips them over the threshold.
Early Warning Signs and REM Sleep Behavior Disorder
One of the strongest early warning signs that synucleinopathy is already underway is a sleep disorder called REM sleep behavior disorder, in which people physically act out their dreams, sometimes violently, during the REM phase of sleep. Prospective studies have shown that patients diagnosed with this sleep disorder face up to an 80 percent risk of eventually developing Parkinson’s, dementia with Lewy bodies, or another synucleinopathy.25PubMed. Prodromal Parkinson’s disease–using REM sleep behavior disorder as a window The conversion can take years or even decades, which creates both an ethical challenge and a scientific opportunity: these patients represent a window into the very earliest stages of disease, before irreversible brain damage has accumulated.
Skin biopsies from patients with REM sleep behavior disorder have detected abnormal phosphorylated alpha-synuclein in the nerve fibers surrounding sweat glands. In one study, this marker showed up in over half of REM sleep behavior disorder patients and in 80 percent of early Parkinson’s patients, while appearing in none of the healthy controls.26PubMed Central. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease Finding the disease protein outside the brain, in an easily biopsied tissue, has opened the door to earlier and less invasive diagnosis.
The Inflammation Connection
Misfolded alpha-synuclein does not just kill neurons directly. It also activates the brain’s immune cells, called microglia, which then launch an inflammatory response. In a healthy brain, microglia help clear debris and maintain the neural environment. But when they encounter clumps of alpha-synuclein, they shift into an attack mode that produces inflammatory molecules, and this chronic inflammation further damages surrounding neurons.27PubMed Central. Alpha-Synuclein and Microglia in Parkinson’s Disease: From Pathogenesis to Therapeutic Prospects
Recent mouse work has revealed that immune cells from the blood, particularly T cells, infiltrate the brain early in the disease process and communicate with microglia in a feedback loop. Removing T cells in these models reduced microglial activation, dampened alpha-synuclein pathology, and protected dopamine neurons. Conversely, depleting microglia suppressed T cell accumulation.28PubMed Central. Microglia-T cell interactions drive α-synuclein pathology in a Parkinson’s disease mouse model This crosstalk between the brain’s resident immune cells and invading blood-borne immune cells appears to amplify neuroinflammation, making it a potential target for future therapies.
When Alzheimer’s Pathology Overlaps
Alpha-synucleinopathy rarely travels alone, especially in older patients. About half of all people with Lewy body disorders have enough amyloid plaque and tau tangle pathology at autopsy to qualify for a secondary diagnosis of Alzheimer’s disease.29PubMed Central. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders This overlap matters clinically because the combination of synuclein and Alzheimer’s pathology is associated with faster cognitive decline, a shorter gap between the onset of movement symptoms and dementia, and a shorter lifespan compared to either pathology alone. Laboratory work suggests these misfolded proteins may actively encourage each other’s spread, with alpha-synuclein fibrils capable of seeding tau pathology across synapses. This co-pathology is one of the reasons that treating synucleinopathies is so difficult: even a perfect alpha-synuclein therapy might not address the Alzheimer’s-related damage accumulating alongside it.
Diagnostic Advances
Until recently, a definitive diagnosis of synucleinopathy could only be confirmed at autopsy by identifying Lewy bodies or glial cytoplasmic inclusions under a microscope. That is changing fast. A technique called seed amplification assay can detect tiny amounts of misfolded alpha-synuclein in cerebrospinal fluid or skin samples by exploiting the protein’s tendency to recruit and misfold normal copies of itself. Essentially, the test gives the pathological seeds a pool of normal protein and watches whether aggregation takes off. These assays can now identify patients with Parkinson’s, dementia with Lewy bodies, and multiple system atrophy.30PubMed. CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps
A skin-based version of the seed amplification assay has shown roughly 91 percent sensitivity and 90 percent specificity in distinguishing Parkinson’s patients from disease controls, making it a practical and less invasive option compared to a spinal tap.31npj Parkinson’s Disease. A skin-specific α-Synuclein seeding amplification assay for diagnosing Parkinson’s disease Researchers have also demonstrated that nasal brushings can serve as a matrix for the assay, opening yet another non-invasive sample source.32npj Parkinson’s Disease. Combining skin and olfactory α-synuclein seed amplification assays (SAA)—towards biomarker-driven phenotyping in synucleinopathies
On the imaging front, teams have recently developed PET tracers that bind to alpha-synuclein deposits in the living brain. Early clinical results show intensified signals in the midbrains of Parkinson’s and dementia with Lewy bodies patients compared to healthy controls, providing the first direct visualization of alpha-synuclein pathology in living people.33Neuron. Visualization of alpha-synuclein pathologies in Parkinson’s disease and related disorders The first clinical PET images of alpha-synuclein in multiple system atrophy have also been published.34PubMed Central. α-synuclein PET Imaging: From Clinical Utility in Multiple System Atrophy to the Possible Diagnosis of Parkinson’s Disease These tracers are still early in development, but they hold enormous promise for tracking disease progression over time and evaluating whether experimental treatments are actually reducing the protein buildup in the brain.
Where Treatments Stand
Current treatments for synucleinopathies manage symptoms — dopamine replacement for Parkinson’s motor symptoms, cholinesterase inhibitors for dementia, blood pressure medications for autonomic failure — but none slows or stops the underlying protein pathology. The most advanced disease-modifying approach in clinical trials is prasinezumab, a monoclonal antibody designed to bind aggregated alpha-synuclein and help the immune system clear it. Early results suggest it may slow motor progression in a subgroup of patients with rapidly progressing early Parkinson’s disease, though the overall trial results have been mixed.35Nature Medicine. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Beyond antibodies, researchers are exploring strategies to reduce the amount of alpha-synuclein the body produces in the first place. These include antisense oligonucleotides, short pieces of synthetic genetic material that block the cell’s instructions for making the protein, effectively turning down the faucet rather than trying to mop up the overflow.36PubMed Central. An update on immune-based alpha-synuclein trials in Parkinson’s disease Because GBA mutations contribute to alpha-synuclein buildup by hobbling the cellular recycling system, therapies aimed at boosting that enzyme’s activity are also in development. The field is moving fast, but the honest assessment is that no therapy has yet proven it can alter the long-term course of any synucleinopathy in humans. The new diagnostic tools, especially seed amplification assays and PET tracers, may be what finally accelerates progress by allowing researchers to identify patients earlier, measure protein burden directly, and see whether a drug is actually doing what it was designed to do.